Moderna's Growth Ambitions Still Outrun Current Revenue
Read source articleWhat happened
Moderna is pushing forward with ambitious oncology investments while its vaccine business struggles to generate sufficient revenue, and the latest article from Zacks highlights the same tension already present in the DeepValue report. The company's Q2 2026 revenue of $145 million and H1 2026 net loss of $2.1 billion show that current vaccine sales are nowhere near covering the fixed costs of manufacturing and R&D, even with the positive melanoma data and flu approval. Cash is declining from $8.14 billion at end-2025 to a guided $4.7-$5.2 billion by year-end 2026 after paying a $950 million litigation settlement, leaving limited room for error. The market has rewarded the stock with a massive rally, but the underlying financials have not yet improved, and the respiratory franchise still must prove it can commercialize at scale. Without clear evidence of revenue conversion, particularly from flu contracting in 2027 and RSV orders, the current share price embeds optimism that is not yet justified by fundamentals.
Implication
The near-term risk-reward remains unattractive at current levels given the disconnect between market enthusiasm and financial reality. Moderna must demonstrate that its respiratory franchise can absorb fixed costs and reduce cash burn, with flu contracting and RSV order conversion as key 2027 milestones. Oncology progress is real but the melanoma filing is still pending and expansion trials are early; the market may be pulling forward value too quickly. A better entry would be around $115 or below, or after a confirmed melanoma filing and improved revenue visibility. Until then, the WAIT rating is appropriate; investors should monitor quarterly results for reduced inventory write-downs and manufacturing charges.
Thesis delta
The article does not alter the investment thesis; it reiterates the central question of whether vaccine revenues can fund oncology ambitions. No new information shifts the balance of evidence; the WAIT rating and $115 attractive entry remain appropriate.
Confidence
high